Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 12/20 | 0.63 |
| ▸ | HTR2B | P41595 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544081 | 0.87 | FASN (0.60) | FASNHTR2BALDH1A1HPGD | |
| SCHEMBL17389876 | 0.85 | FASN (0.63) | FASN | |
| SCHEMBL17389966 | 0.85 | FASN (0.63) | FASN | |
| SCHEMBL17389668 | 0.84 | FASN (0.55) | FASN | |
| SCHEMBL17389962 | 0.83 | FASN (0.55) | FASN | |
| SCHEMBL17390000 | 0.83 | FASN (0.63) | FASNHTR2B | |
| SCHEMBL16620370 | 0.82 | HPGD (0.60) | HTR2BKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL17389704 | 0.79 | FASN (0.64) | FASN | |
| SCHEMBL16150702 | 0.78 | CHEK2 (0.56) | HTR2BKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL17390003 | 0.78 | HTR2B (0.57) | HTR2BKDM4EALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | claimed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-2968316-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | Forma Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014164749-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2100/4885KDM4E 4419/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2100/4885KDM4E 4419/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2971/4885KDM4E 4486/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | FASN 3/4885HTR2B 3423/4885KDM4E 3760/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2525/4885KDM4E 4564/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2100/4885KDM4E 4419/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2100/4885KDM4E 4419/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2100/4885KDM4E 4419/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | FASN 1/4885HTR2B 2193/4885KDM4E 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.